canada clinical guidance

Urinary incontinence & pelvic organ prolapse (women)

A Canadian clinical summary of urinary incontinence & pelvic organ prolapse (women), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Guideline No. 397: Conservative Care of Urinary Incontinence in Women. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 397

Source-attributed clinical priorities

  • Classify stress, urgency, mixed, overflow and functional contributors and assess prolapse, retention, infection and hematuria.
  • Begin pelvic-floor, bladder, fluid and contributing-medication interventions matched to the phenotype.
  • Discuss pessary, medication and surgery through shared decisions, referring pain, bleeding, obstruction or complex recurrence.
  • Determine whether leakage is stress, urgency, overflow, functional or mixed before choosing treatment.
sources for this section:SOGC 397

Practical assessment and management workflow

1
Record bladder diary, fluid and caffeine, bowel function, births, pelvic symptoms, medicines and neurologic features.
2
Examine abdomen and pelvis with consent and measure urinalysis and residual urine when indicated.
3
Begin pelvic-floor, bladder training and reversible-contributor care matched to the phenotype.
4
Review response and discuss pessary, medication or surgical referral around goals and risks.
sources for this section:SOGC 397

Safety, red flags and urgent escalation

  • Acute retention, hematuria, recurrent infection, hydronephrosis or major neurologic change needs urgent assessment.
  • Check anticholinergic cognitive and retention risk before bladder medicine.
  • Ulcerated, incarcerated or obstructive prolapse requires prompt gynecologic evaluation.
sources for this section:SOGC 397

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 397

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 397

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Society of Obstetricians and Gynaecologists of CanadaGuideline No. 397: Conservative Care of Urinary Incontinence in Womenaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.